(•100 ìÒ) stimulate activity. The stimulatory effect requires the presence of Mg¥ while the inhibitory effect is independent of the cation. The molecular identity of the â-cell KATP channel has recently been resolved. It is a complex of (at least) two different proteins, both of which are required for the formation of a functional KATP channel (Inagaki et al. 1995; Sakura, Amm al a, Smith, Gribble & Ashcroft, 1995) . One of these proteins is an inwardly rectifying K¤ channel subunit (Kir6.2) and it is likely that four of these subunits come together to form the channel pore (Clement et al. 1997) . The other subunit is a sulphonylurea receptor (SUR1; Aguilar-Bryan et al. 1995) , which acts as a regulator of channel activity ( Amm al a, Moorhouse & Ashcroft, 1996a; Inagaki et al. 1996) . Both subunits are required for functional KATP channels since expression of Kir6.2 alone does not result in measurable currents. Truncation of the last thirty-six residues of Kir6.2 (Kir6.2ÄC36), however, enables functional expression of the protein in the absence of SUR1 (Tucker, Gribble, Zhao, Trapp & Ashcroft, 1997) . Studies of Kir6.2ÄC36 expressed in the absence and presence of SUR1 have shown that the site at which ATP and ADP mediate channel inhibition lies on Kir6.2, while SUR1 confers sensitivity to the sulphonylureas, diazoxide and the stimulatory effects of MgADP . SUR1 is a member of the ATP-binding cassette (ABC) transporter superfamily (Higgins, 1992) , and its predicted membrane topology consists of thirteen to seventeen transmembrane domains with two large intracellular loops which contain consensus sequences for nucleotide binding. Each nucleotide binding domain (NBD) contains a highly conserved Walker A (WA) and Walker B (WB) motif (Walker, Saraste, Runswick & Gay, 1982) . Mutations in either of these domains abolish the ability of MgADP to stimulate channel activity (Nichols et al. 1996; Gribble, Tucker & Ashcroft, 1997b) . In other ATPases and ABC transporters a lysine residue in the WA motif is essential for ATP hydrolysis (Azzaria, Schurr & Gros, 1989; Saraste, Sibbald & Wittinghofer, 1990; Tian, Yan, Jiang, Kishi, Nakazawa & Tsai, 1990; Higgins, 1992; Ko & Pedersen, 1995; Koronakis, Hughes, Milislav & Koronakis, 1995) . Mutation of this residue in either of the NBDs of SUR1 abolishes the potentiatory effect of MgADP and reveals an inhibitory effect of the nucleotide diphosphate on the KATP channel (Gribble et al. 1997b ). The extent of this inhibition is the same as that observed for wild-type channels in the absence of Mg¥, and supports the view that the nucleotide has both stimulatory and inhibitory effects on the KATP channel (Ashcroft & Rorsman, 1989 ; Bokvist, Amm al a, Ashcroft, Berggren, Larsson & Rorsman, 1991) . A conserved aspartate residue in the WB motif is required for MgATP binding in other ATPases and ABC transporters, and is thought to co-ordinate the Mg¥ ion of MgATP (Azzaria et al. 1989; Saraste et al. 1990; Tian et al. 1990; Higgins, 1992; Ko & Pedersen, 1995) . Mutation of this residue in the second NBD (NBD2) of SUR1 also abolishes the stimulatory action of MgADP on KATP channel activity (Nichols et al. 1996) . In this paper we have investigated the effects of nucleotide diphosphates on the sensitivity of the KATP channel to tolbutamide. We provide evidence that tolbutamide interacts with both a high-affinity and a low-affinity site to inhibit KATP channel currents and that the high-affinity site resides on SUR1, whereas the low-affinity site is located on Kir6.2. Previous studies have assumed that tolbutamide interacts with the KATP channel at a single site (Z unkler et al. 1988; Schwanstecher et al. 1992 Schwanstecher et al. , 1994 . If a single-site, rather than a two-site, model is used, the Ki for tolbutamide inhibition appears to shift in the presence of MgADP. This finding led to the earlier idea that the nucleotide alters the affinity of the â-cell KATP channel for sulphonylureas. We now show that this idea is incorrect, because the Ki for tolbutamide interaction with the high-affinity site is unaffected by MgADP. Instead, our results suggest that the interaction of tolbutamide with SUR1 abolishes the stimulatory action of MgADP. This unmasks the inhibitory effect of MgADP and leads to an apparent increase in channel inhibition. Under physiological conditions, reduction of MgADP activation is likely to constitute the principal mechanism by which tolbutamide inhibits the KATP channel.
METHODS

Molecular biology
Site-directed mutagenesis was carried out by subcloning the appropriate fragments into the pALTER vector (Promega, Madison, WI, USA). The lysine residues at position 719 or 1384 of SUR1 were replaced by an alanine or methionine, respectively (K719A, K1384M). The C_terminal deletion of Kir6.2 (Kir6.2ÄC36) was created by introduction of a stop codon at residue 355. Synthesis of mRNA encoding Kir6.2ÄC36 or wild-type mouse Kir6.2 (Genbank D50581), and of wild-type and mutant rat SUR1 (Genbank L40624) was carried out as previously described (Gribble et al. 1997b ). All SUR1 mutations were coexpressed with wild-type Kir6.2 and the resulting currents are referred to by the SUR1 mutation only (thus, wild-type Kir6.2 plus SUR1-K719A currents are referred to as K719A currents). The term wild-type KATP current refers to wild-type Kir6.2 coexpressed with wild-type SUR1.
Electrophysiology
Oocyte collection. Female Xenopus laevis were anaesthetized with MS-222 (2 g l¢ added to the water). One ovary was removed via a mini-laparotomy, the incision sutured and the animal allowed to recover. Once the wound had completely healed, the second ovary was removed in a similar operation and the animal was then killed by decapitation whilst under anaesthesia.
Oocyte preparation. Immature stage V-VI Xenopus oocytes were incubated for 75 min with 1·5 mg ml¢ collagenase (Type A; Boehringer) and manually defolliculated. They were then coinjected with •2 ng each of mRNAs encoding wild-type Kir6.2 and either wild-type or mutant SUR1, or injected with Kir6.2ÄC36 alone (Gribble, Ashfield, Amm al a & Ashcroft, 1997a) . Control oocytes were injected with water. The final injection volume was •50 nl per oocyte in all cases. Isolated oocytes were maintained in modified F. M. Gribble, S. J. Tucker and F. M. Ashcroft Barth's solution containing (mÒ): 88 NaCl, 1 KCl, 1·7 MgSOÚ, 0·47 Ca(NO×)µ, 0·41 CaClµ, 2·4 NaHCO×, 10 Hepes (pH 7·4 with NaOH); supplemented with 100 U ml¢ penicillin, 100 ìg ml¢ streptomycin and 5 mÒ pyruvate. Currents were studied 1-4 days after injection.
Giant patch recordings. Macroscopic currents were recorded from giant excised inside-out patches (Hilgemann, Nicoll & Phillipson, 1991) at 20-24°C. Patch electrodes were pulled from thick-walled borosilicate glass (GC150; Clark Electromedical Instruments, Pangbourne, UK) and had resistances of 200-400 kÙ when filled with pipette solution. Currents were evoked by repetitive 4 s voltage ramps from −110 to +100 mV (holding potential, 0 mV), recorded using an EPC7 patch-clamp amplifier (List Electronik, Darmstadt, Germany) and stored on videotape for later analysis. They were subsequently filtered at 0·2 kHz, digitized at 0·5 kHz using a Digidata 1200 Interface and analysed using pCLAMP software (Axon Instruments). The pipette solution contained (mÒ): 140 KCl, 1·2 MgClµ, 2·6 CaClµ, 10 Hepes (pH 7·4 with KOH), and the internal (bath) solution contained (mÒ): 110 KCl, 1·44 MgClµ, 30 KOH, 10 EGTA, 10 Hepes (pH 7·2 with KOH) and nucleotides as indicated. Tolbutamide was made up as a 0·1 Ò stock solution in 0·1 Ò KOH, and diluted as required. Rapid exchange of solutions was achieved by positioning the patch in the mouth of one of a series of adjacent inflow pipes placed in the bath.
Data analysis
The slope conductance was measured by fitting a straight line to the current-voltage relation between −20 and −100 mV: the average of five consecutive ramps was calculated in each solution. Dose-response relations for tolbutamide block of KATP currents were obtained by alternating test solutions with control (drug-and nucleotide-free) solutions. To control for run-down, the control conductance was taken as the mean of that obtained in the control solution before and after application of the test compound. Most currents were not leak corrected because the leak current (that remaining in the presence of 1 mÒ ATP) was < 1 % of the total current. However, as the amplitude of Kir6.2ÄC36 currents was smaller, we corrected the dose-response curves for leak by subtraction of the mean conductance measured in patches excised from control oocytes. The conductance (G) is plotted as a fraction of that obtained in the control solution (Gc). In each case, the dose-response curve was fitted with the following equation: GÏGc = ABxy, (1) where A is a factor describing the activation of the fractional conductance by nucleotide; B is a factor describing the block of the fractional conductance by nucleotide (both A and B have a value of one in the absence of nucleotide diphosphate); x is a term describing the high-affinity site and y is a term describing the lowaffinity site.
where [Tolb] is the tolbutamide concentration, Ki1 and Ki2 are the tolbutamide concentrations at which inhibition is half-maximal at the high-and low-affinity sites, respectively; h1 and h2 are the Hill coefficients (slope factors) for the high-and low-affinity sites, respectively; and L is the fractional conductance remaining when all of the high-affinity inhibitory sites are occupied. When only a single binding site is present, eqn (1) reduces to: GÏGc = ABy.
(4) In most cases, data are given as means ± 1 s.e.m., and the symbols in the figures indicate the mean and the vertical bars indicate 1 s.e.m. (where this is larger than the symbol). In the case of the Ki, the statistics were carried out on log-transformed data and are presented as the geometric mean (with 1 s.e.m. range). Statistical significance was tested using Student's unpaired t test or ANOVA, as appropriate. P values of < 0·05 were taken to indicate that the data were significantly different.
RESULTS
Tolbutamide block of wild-type channels
The inhibitory effect of tolbutamide on wild-type KATP currents is shown in Fig. 1A . As previously reported for native KATP currents, the drug inhibited wild-type Kir6.2-SUR1 currents in a voltage-independent fashion. Tolbutamide (0·5 mÒ) blocked the slope conductance by 59·1 ± 4·3 % (n = 11; Fig. 3 ). The extent of this inhibition was considerably less than that found for wild-type KATP currents when the drug was applied to the extracellular surface of the membrane of intact oocytes; under these conditions, 0·5 mÒ tolbutamide blocked the current at −100 mV by 96% (Gribble et al. 1997a ). A similar difference has been observed for native â_cell KATP channels, where it was attributed to the presence of MgADP at the inner surface of the membrane in intact cells (Z unkler et al. 1988 ). Figure 1B shows that when tolbutamide was applied in the presence of intracellular MgADP the extent of inhibition of the KATP current was enhanced. Tolbutamide (0·5 mÒ) blocked the wild-type KATP conductance by 84 ± 2 % (n = 8) in the presence of 100 ìÒ MgADP, compared with 59 % in the absence of the nucleotide diphosphate ( Fig. 3 ). Furthermore, whereas 100 ìÒ MgADP caused a marked activation of KATP currents when applied by itself ( Fig. 1C ), the nucleotide diphosphate was actually inhibitory when applied in the presence of tolbutamide ( Fig. 1D ). Similar findings with native KATP channels have been used to argue that MgADP potentiates the tolbutamide block by making the channel more sensitive to tolbutamide (Z unkler et al. 1988; Schwanstecher et al. 1992 Schwanstecher et al. , 1994 . However, since MgADP has both stimulatory and inhibitory effects on KATP channel activity (Bokvist et al. 1991; Gribble et al. 1997b; Tucker et al. 1997) , an alternative interpretation is that tolbutamide abolishes the potentiatory effect of MgADP, so unmasking its inhibitory effect. This idea is supported by the fact that the extent of block by 100 ìÒ MgADP in the presence of tolbutamide was not significantly different from the inhibitory effect of 100 ìÒ ADP in Mg¥free solution (Fig. 4) , a condition in which the stimulatory action of MgADP is abolished.
Tolbutamide inhibition of mutant channel currents
To further investigate the possibility that tolbutamide abolishes the potentiatory effect of MgADP, we studied the Tolbutamide block of KATP channels interaction between MgADP and tolbutamide on mutant KATP channels in which the stimulatory effect of MgADP was selectively abolished. Mutation of the WA lysine residues in either NBD1 (K719A) or NBD2 (K1384M), or both (K719A-K1384M) prevented the MgADP activation of KATP currents and unmasked the inhibitory effect of MgADP (Figs 2C and 4; Gribble et al. 1997b ). In the absence of nucleotides, the extent of block of K719A-K1384M, K719A and K1384M currents by 0·5 mÒ tolbutamide was similar to that of wild-type channels (Fig. 3 ). This suggests that the WA lysines are not required either for tolbutamide binding or for the transduction of tolbutamide binding into inhibition of the KATP channel. Addition of 100 ìÒ MgADP to the cytosolic side of the membrane blocked Macroscopic currents recorded from inside-out patches in response to a series of voltage ramps from −110 to +100 mV (holding potential, 0 mV). The oocytes were coinjected with mRNAs encoding wild-type Kir6.2 and wild-type SUR1. MgADP (100 ìÒ) and tolbutamide (0·5 mÒ) were added to the internal (bath) solution as indicated.
Figure 2. Effects of MgADP and tolbutamide on K719A-K1384M currents
Macroscopic currents recorded from inside-out patches in response to a series of voltage ramps from −110 to +100 mV (holding potential, 0 mV). The oocytes were coinjected with mRNAs encoding wild-type Kir6.2 and K719A-K1384M SUR1. MgADP (100 ìÒ) and tolbutamide (0·5 mÒ) were added to the internal (bath) solution as indicated.
K719A-K1384M currents by 67% (Fig. 2C ). This contrasts with its stimulatory action on wild-type KATP channels ( Fig. 4 ; Gribble et al. 1997b ). Furthermore, MgADP did not enhance tolbutamide inhibition of K719A-K1384M currents (Figs 2 and 3) . Similar results were observed for K719A and K1384M currents (Figs 3 and 4) , which confirms that the WA lysine at each of the NBDs of SUR1 is needed both for the stimulatory effect of MgADP itself (Gribble et al. 1997b) , and for the ability of MgADP to enhance tolbutamide block. Mutation of the WB aspartate residues in either NBD1 (D853N) or NBD2 (D1505N) of SUR1 abolished the stimulatory effects of MgADP on KATP currents ( Fig. 4 ) and prevented the MgADP-dependent enhancement of tolbutamide block (Fig. 3) . These mutations are predicted to prevent the interaction of the Mg¥ ion of MgADP with the Tolbutamide block of KATP channels J. Physiol. 504.1 39 Figure 3 . Mean effects of tolbutamide on wild-type and mutant KATP channels Mean macroscopic conductance of wild-type or mutant KATP channels recorded in response to 0·5 mÒ tolbutamide with (fi) or without (4) 100 ìÒ MgADP. Conductance is expressed as a percentage of its amplitude in the absence of tolbutamide (GTolbÏGc). The dashed line indicates the conductance of wild-type channels in the presence of 0·5 mÒ tolbutamide (ADP free) solution. The number of patches is indicated in parentheses. Oocytes were injected with wild-type Kir6.2 and mutant SUR1 as indicated. NBDs of SUR1. The results indicate that the WB aspartates at both NBDs of SUR1 are needed not only for the activatory effect of MgADP but also for the ability of the nucleotide to enhance tolbutamide block.
Effects of nucleotides on the dose-response relation for tolbutamide block
The relation between tolbutamide concentration and the amplitude of the wild-type KATP conductance is given in Fig. 5 . It is clear that the dose-response curve cannot readily be fitted by a single-site model. Instead, the data indicate that tolbutamide blocks at both a high-affinity and a low-affinity site and that occupation of the high-affinity site produces a maximum of 57% inhibition. When the dose-response curve was fitted to a two-site model (eqn (1)), the best fit was obtained with a mean Ki of 2·0 ìÒ (1·2-3·5 ìÒ) and a Hill coefficient of 1·0 ± 0·1 for the highaffinity site and a Ki of 1·8 mÒ (1·4-2·3 mÒ) and a Hill coefficient of 1·3 ± 0·2 for the low-affinity site (n = 8). The Hill coefficients were close to unity for both sites, which suggests that only a single tolbutamide molecule need interact with either site to cause channel inhibition. Relationship between tolbutamide concentration and the macroscopic KATP conductance, expressed as a fraction of its amplitude in the absence of the drug (GÏGc). 0 (continuous line), wild-type KATP currents, (n = 8). 1 (dashed line), K719A-K1384M currents (n = 6). The lines are the best fit of the data to eqn (1). Wild-type Kir6.2-SUR1 channel currents: Ki1 = 2·0 ìÒ, h1 = 1·0, Ki2 = 1·8 mÒ, h2 = 1·3, L = 0·43. K719A-K1384M channel currents: Ki1 = 1·6 ìÒ, h1 = 0·7, Ki2 = 2·1 mÒ, h2 = 1·4, L = 0·40.
Figure 6. Effects of MgADP and MgGDP on the relation between KATP conductance and tolbutamide concentration
A, relation between tolbutamide concentration and the macroscopic KATP conductance, expressed as a fraction of its amplitude in control solution (GÏGc) lacking both drug and nucleotide. 0, wild-type currents, no nucleotides (n = 8). þ, wild-type currents, 100 ìÒ MgADP (n = 8). ±, K719A-K1384M currents, 100 ìÒ MgADP (n = 6). The lines are the best fit of the data to eqn (1). In the presence of 100 ìÒ MgADP: Ki1 = 6·6 ìÒ, h1 = 1·1, Ki2 = 4·3 mÒ, h2 = 1·0, L = 0·13, A = 4·3, B = 0·33, for wild-type channel currents; and Ki1 = 3·1 ìÒ, h1 = 1·2, Ki2 = 5·5 mÒ, h2 = 1, L = 0·44, A = 1·0, B = 0·33, for K719A-K1384M currents. B, mean relationship between tolbutamide concentration and the macroscopic KATP conductance, expressed as a fraction of its amplitude in control solution lacking both drug and nucleotide. 0, wildtype currents, no nucleotides (n = 8). 8, wild-type currents, 100 ìÒ MgGDP (n = 6). 9, K719A-K1384M currents, 100 ìÒ MgGDP (n = 6). The lines are the best fit of the data to eqn (1). In the presence of 100 ìÒ MgGDP: Ki1 = 6·0 ìÒ, h1 = 1·0, Ki2 = 2·0 mÒ, h2 = 1·0, L = 0·39, A = 1·9, B = 0·9, for wild-type channel currents; and Ki1 = 3·8 ìÒ, h1 = 1·0, Ki2 = 2·8 mÒ, h2 = 1·3, L = 0·56, A = 1·0, B = 0·9, for K719A-K1384M currents.
We next examined the dose-response curve for tolbutamide block of K719A-K1384M currents. In the absence of nucleotides, the dose-inhibition curve was not significantly different from that of the wild-type channel and could be well fitted with the same parameters (Fig. 5) . The best fit to the WA mutant channel currents was obtained with a Ki of 1·6 ìÒ (1·1-2·4 ìÒ) and a Hill coefficient of 0·7 ± 0·1 for the high-affinity site and a Ki of 2·1 mÒ (1·8-2·5 mÒ) and a Hill coefficient of 1·4 ± 0·2 for the low-affinity site (n = 6). This provides further support for the idea that mutation of the WA lysines does not influence the tolbutamide sensitivity of the KATP channel. We next examined the effects of intracellular MgADP on the efficacy of tolbutamide block (Fig. 6A ). In the absence of the drug, MgADP caused a marked activation of wild-type KATP currents (155 ± 13 %, n = 5). The dose-response curve for tolbutamide block was also altered. In particular, greater inhibition was observed at high tolbutamide concentrations in the presence of MgADP. The Ki and Hill coefficient for the high-affinity site were 6·6 ìÒ (4·9-8·9 ìÒ) and 1·1 ± 0·1, respectively (n = 5) in the presence of 100 ìÒ MgADP. These values are not significantly different (t test) from those obtained in the absence of MgADP, which suggests that MgADP does not markedly alter the sensitivity of the wild-type KATP channel to tolbutamide. The small size of the currents at high tolbutamide concentrations in the presence of MgADP precludes an accurate analysis of the Ki of the low-affinity site in this solution. Unlike wild-type KATP currents, K719A-K1384M channel currents were blocked by 100 ìÒ MgADP (by 63·4 ± 2·8 %, n = 17). Tolbutamide caused a further block at all concentrations without affecting the shape of the dose-response curve (Fig. 6A ). There was no detectable difference in the Ki of the high-affinity site measured in the presence or absence of MgADP. The best fit to the mutant channel currents in 100 ìÒ MgADP was obtained with a Ki of 3·1 ìÒ (2·1-4·7 ìÒ, n = 5), which is not significantly different (ANOVA) from that of wild-type currents, or K719A-K1384M currents in the absence of ADP. The Hill coefficient for the high-affinity site was 1·2 ± 0·1 (n = 5). The most likely explanation for our results is that binding of tolbutamide to the high-affinity site produces a concentrationdependent inhibition of the stimulatory action of MgADP, and so unmasks the inhibitory effect of the nucleotide. This would account for the fact that MgADP has no effect on the tolbutamide block of K719A-K1384M currents, which are not stimulated by the nucleotide. It is also consistent with the finding that at high tolbutamide concentrations the dose-response curves for wild-type and mutant channels converge ( Fig. 6A ), suggesting that the stimulatory effect on MgADP on wild-type KATP channels is abolished. If this idea is correct, we would expect that nucleotides which Tolbutamide block of KATP channels J. Physiol. 504.1 41 Figure 7 . Effect of tolbutamide on Kir6.2ÄC36 currents A, macroscopic currents recorded from an inside-out patch in response to a series of voltage ramps from −110 to +100 mV (holding potential, 0 mV). The oocyte was injected with mRNA encoding Kir6.2ÄC36. Tolbutamide (5 mÒ) was added to the internal solution as indicated. B, mean relation between tolbutamide concentration and the macroscopic Kir6.2ÄC36 conductance, expressed as a fraction of its amplitude in the absence of the drug (GÏGc), in the absence (0, continuous line; n = 6) or presence (1, dashed line; n = 4) of 100 ìÒ MgADP. The lines are the best fit of the data to eqn (4), with: Ki = 1·7 mÒ, h = 1·2, A = 1, B = 1 (continuous line); and Ki = 1·9 mÒ, h = 1·5, A = 1, B = 0·72 (dashed line). The currents have been corrected for leak by subtraction of the mean conductance of patches excised from water-injected oocytes. potentiate activity, but which have minimal blocking effect, such as MgGDP, should not enhance the tolbutamide block. We therefore next explored this possibility. In contrast to MgADP, 100 ìÒ MgGDP had little effect on K719A-K1384M currents, which were 90 ± 3 % (n = 6) of their amplitude in control solution. This indicates that the guanine nucleotide is much less effective at the inhibitory nucleotide-binding site (Fig. 6B) , in agreement with the fact that 100 ìÒ MgGDP causes little or no block of Kir6.2ÄC26 currents . MgGDP was, however, a potent activator of wild-type channels, enhancing the macroscopic conductance by 173 ± 15 % (n = 6). This confirms that MgGDP is able to act at the stimulatory nucleotide-binding site in wild-type, but not K719A-K1384M, channels. Tolbutamide produced a concentration-dependent inhibition of wild-type currents in the presence of MgGDP, but even at high drug concentrations the block never exceeded that found in the absence of the nucleotide. In the presence of 100 ìÒ MgGDP, the Ki values were 6·0 ìÒ (4·7-7·6 ìÒ) and 2·0 mÒ (1·6-2·5 mÒ), and the Hill coefficients were 1·0 ± 0·1 and 1·0 ± 0·2, for the high-and low-affinity sites, respectively (n = 6). These values are not significantly different from those obtained in the absence of MgGDP (by t test). The best fit to the mutant channel currents was obtained with a Ki of 3·8 ìÒ (1·9-7·6 ìÒ) and a Hill coefficient of 1·0 ± 0·02 for the high-affinity site and a Ki of 2·8 mÒ (2·2-3·5 mÒ) and a Hill coefficient of 1·3 ± 0·1 for the low-affinity site (n = 6). The convergence of the dose-response curves for wild-type and mutant channels at high tolbutamide concentrations (Fig. 6B) suggests that activation of wild-type currents by MgGDP is abolished by the drug.
The low-affinity site may reside on Kir6.2 We next explored whether the low-affinity site lies on the sulphonylurea receptor or on Kir6.2 by studying the effect of tolbutamide on the Kir subunit in the absence of SUR1. Expression of Kir6.2 alone does not result in measurable KATP currents (Sakura et al. 1995; Inagaki et al. 1995) . We therefore examined the effect of tolbutamide on a mutant form of Kir6.2 (Kir6.2ÄC36) in which the last thirty-six Cterminal amino acids had been deleted: expression of this protein produces large currents in the absence of SUR1 . Mean Kir6.2ÄC36 currents upon patch excision were 1·0 ± 0·2 nA (n = 6) at −100 mV. Figure 7A shows that these currents were blocked by high concentrations of tolbutamide. The dose-response curve for tolbutamide inhibition (Fig. 7B) was well fitted by a singlesite model with a Ki of 1·7 mÒ (1·7-1·8 mÒ, n = 6) and a Hill coefficient of 1·2 ± 0·1 (n = 6). These values are not significantly different from those obtained for the lowaffinity site of wild-type KATP (Kir6.2-SUR1) currents (Ki = 1·8 mÒ, h = 1·0). These data confirm that the highaffinity binding site for sulphonylureas resides on SUR1 (Aguilar-Bryan et al. 1995). They also suggest that the lowaffinity site resides on Kir6.2.
We tested whether MgADP interacted with the low-affinity site for tolbutamide directly, by measuring the dose-response curve for tolbutamide inhibition of Kir6.2ÄC36 currents in the presence of 100 ìÒ MgADP (Fig. 7B ). The mean Ki was 1·9 mÒ (1·7-2·1 mÒ, n = 4) and the mean Hill coefficient was 1·5 ± 0·2 (n = 4), values which are not significantly different (t test) from those found in the absence of MgADP.
Thus, it appears that MgADP at this concentration does not affect the low-affinity site.
DISCUSSION
Our results indicate that tolbutamide interacts with two sites to inhibit wild-type KATP currents, which have Ki values of •2 ìÒ and •2 mÒ. The former value is in good agreement with previous reports for both native â-cell (7 ìÒ; Panten et al. 1989 ) and cloned (4 ìÒ; Sakura et al. 1995 ) KATP channels in whole-cell recordings. The presence of two sites which mediate sulphonylurea inhibition of KATP channel currents is consistent with the results of studies of the binding of [ÅH]glibenclamide to â-cell membranes, which have also shown both high-and low-affinity sulphonylurea receptors (Ashcroft & Ashcroft, 1992) . The Ki for tolbutamide displacement of [ÅH]glibenclamide binding to the high-affinity binding site was 15-25 ìÒ, close to that observed for high-affinity inhibition of KATP currents in the present study. This suggests that tolbutamide binds to the high-affinity sulphonylurea receptor to mediate highaffinity inhibition of KATP currents. No Ki value for tolbutamide displacement of [ÅH]glibenclamide binding to the low-affinity binding site of â-cell membranes has been reported. However, [ÅH]glibenclamide binds approximately 1000 times less strongly to the low-affinity binding site of HIT T15 insulinoma cell membranes (Niki, Kelly, Ashcroft & Ashcroft, 1989; Aguilar-Bryan, Nelson, Vu, Humphrey & Boyd, 1990) . Since the Ki for low-affinity tolbutamide inhibition of the cloned KATP channels obtained in this study was also 1000 times greater than that for high-affinity inhibition, this may suggest that the low-affinity inhibition we observed is mediated by tolbutamide binding to the lowaffinity site observed in sulphonylurea-binding studies. Furthermore, in at least one of the binding studies, the number of high-and low-affinity binding sites was the same (•546 vs. 575 fmol (mg protein)¢; Niki et al. 1989) , in agreement with the 1:1 stoichiometry observed for Kir6.2 and SUR1 (Clement et al. 1997; Inagaki, Gonoi & Seno, 1997) . Interaction of tolbutamide with the high-affinity site blocks the macroscopic KATP conductance by about 50%. It is difficult to explain why this block is not complete. It cannot result from a partial reduction of the single-channel current amplitude since single-channel recordings have shown that tolbutamide has no effect on the single-channel conductance but affects only the channel open probability (Trube, Rorsman & Ohno-Shosaku, 1986; Gillis, Gee, Hammoud, McDaniel, Falke & Misler, 1989) . It also cannot be explained by postulating that only 50% of KATP channels are F. M. Gribble, S. J. Tucker and F. M. Ashcroft associated with a sulphonylurea receptor, because wild-type Kir6.2 does not form functional channels in the absence of SUR1. One possibility is that the high-affinity binding site for tolbutamide can exist in two states, one of which induces KATP channel inhibition and one which has no effect on channel activity, and that there is an approximately equal probability of being in either state. (Our results do not allow us to distinguish whether channels that are unaffected by the drug simply do not bind tolbutamide, or whether they fail to translate the effect of tolbutamide binding into closure of the KATP channel pore.)
Identity of the two sulphonylurea-binding sites
There is good evidence that the high-affinity site which mediates tolbutamide inhibition of KATP channel currents resides on SUR1. First, the Ki for tolbutamide displacement of [ÅH]glibenclamide binding to SUR1 in the absence of Kir6.2 was 59 ìÒ ( Amm al a et al. 1996b), a value which is closest to that of the high-affinity site which regulates KATP currents. Second, in the absence of SUR1, Kir6.2ÄC36 currents do not show high-affinity inhibition by tolbutamide. The low-affinity site is present when Kir6.2ÄC36 currents are expressed independently of SUR1. It must therefore reside on Kir6.2, or on a separate protein, endogenously expressed in Xenopus oocytes, which regulates Kir6.2 activity. Although we cannot exclude the latter possibility, we favour the idea that Kir6.2 is itself sensitive to sulphonylureas. This is because Kir6.2ÄC36 currents were expressed at high levels in oocytes and were completely blocked by 10 mÒ tolbutamide; thus, an endogenous oocyte protein would also have to be expressed at a similar high density.
Effects of MgADP on tolbutamide inhibition of KATP channels
The dose-inhibition curve for tolbutamide in the presence of nucleotide diphosphates is best fitted with a two-site model, as it is under control conditions. Neither MgADP nor MgGDP markedly altered the Ki for tolbutamide inhibition at either the high-or low-affinity site. This suggests that nucleotide diphosphates do not measurably alter the affinity of the interaction between the drug and the KATP channel, in contrast to previous suggestions (Z unkler et al. 1988; Schwanstecher et al. 1992 Schwanstecher et al. , 1994 . It is well established that ADP has both potentiatory and inhibitory effects on the KATP channel (Bokvist et al. 1991; Gribble et al. 1997b; Tucker et al. 1997) . The greater inhibition of KATP channel currents by tolbutamide in the presence of MgADP is most easily explained by assuming that the drug reduces the stimulatory action of MgADP and thereby unmasks the inhibitory action of the nucleotide diphosphate. Several findings support this idea. First, we observed no significant difference in the Ki of either the high-or low-affinity sites in the presence and absence of MgADP. Second, the tolbutamide block of K719A-K1384M currents, which are not potentiated by MgADP, was not altered by MgADP. Third, tolbutamide inhibition of Kir6.2ÄC36 currents, which are also not potentiated by MgADP, was unaffected by the nucleotide. Fourth, MgGDP, at a concentration which produces activation but not inhibition of KATP currents, did not support an enhanced block by tolbutamide. Since Mg¥ is required for the stimulatory effects of MgADP and MgGDP (Bokvist et al. 1991; Gribble et al. 1997b) , our results may also explain why nucleotide diphosphates only influence tolbutamide inhibition of KATP currents in the presence of Mg¥; in the absence of Mg¥, the effects of ADP would resemble those found for K719A-K1384M currents.
Mechanism of tolbutamide block
The mechanism by which tolbutamide inhibits the MgADP potentiation of channel activity is not clear. Nucleotide diphosphates mediate their stimulatory effects by interaction with the NBDs of SUR1 (Nichols et al. 1996; Gribble et al. 1997b) . One possibility, therefore, is that binding of tolbutamide to SUR1 prevents the interaction of MgADP with either or both NBDs. Another idea is that tolbutamide disrupts the mechanism by which the interaction of MgADP with the NBDs of SUR1 is translated into KATP channel activation. We emphasize that this does not necessarily mean that tolbutamide interacts directly with the NBDs of SUR1 − it may simply mediate its effects allosterically by binding to a site elsewhere on SUR1. Mutation of either the WA lysine or the WB aspartate in a single NBD of SUR1 is sufficient to abolish the stimulatory effect of MgADP (Nichols et al. 1996; Gribble et al. 1997b ). We cannot tell whether tolbutamide prevents the stimulatory action of MgADP at NBD1 or NBD2, or both, because the enhancement of channel activity by MgADP is abolished if either one of the NBDs is mutated.
Reinterpretation of previous studies
Previous studies have fitted tolbutamide dose-inhibition curves with a single-site model in both the presence and absence of intracellular nucleotide diphosphates (Z unkler et al. 1988; Schwanstecher et al. 1992 Schwanstecher et al. , 1994 . Our data show that this is inappropriate. In the absence of nucleotide diphosphates, tolbutamide clearly interacts with two sites to inhibit the wild-type KATP channel, one of which has a high affinity and the other a low affinity for the drug. This is easily discerned in our studies because the high expression levels of cloned KATP channels in Xenopus oocytes allows a more accurate determination of the dose-response relation, but it is not always so readily apparent in â-cells and the data have traditionally been fitted with a single-site model. However, careful re-examination of the tolbutamide dose-response curve in â-cells (e.g. Schwanstecher et al. 1994) confirms that they may also be better fitted with a two-site model, suggesting that tolbutamide also inhibits the native â-cell KATP channel by interaction with both a high-and a low-affinity site. The model used to fit the tolbutamide dose-response curve has functional implications. If a single-site, rather than a Tolbutamide block of KATP channels two-site, model is used, the Ki for tolbutamide inhibition appears to shift in the presence of MgADP (Z unkler et al. 1988; Schwanstecher et al. 1992 Schwanstecher et al. , 1994 . For example, an apparent shift in Ki from 55 to 14 ìÒ, in the absence and presence of 100 ìÒ MgADP, respectively, was observed when a single-binding site model was used to fit the tolbutamide dose-response curve (Z unkler et al. 1988) . This led to the idea that the nucleotide alters the affinity of the â_cell KATP channel for sulphonylureas. It is clear from our studies that this is not the case. Rather, tolbutamide not only has a direct inhibitory action but also appears to have the additional effect of reducing the stimulatory action of MgADP.
Physiological significance
In the normal â-cell, glucose metabolism causes KATP channel closure. Recent studies argue that this is principally mediated by the fall in intracellular MgADP, rather than the concomitant rise in ATP (Nichols et al. 1996; Gribble et al. 1997b) . At therapeutic concentrations (1-10 ìÒ), our results indicate that the primary mechanism by which tolbutamide blocks the KATP channels is by reducing the potentiatory effects of MgADP. Thus, both glucose and tolbutamide mediate their inhibitory effects on the KATP channel by modulating the stimulatory action of MgADP: the former directly alters the MgADP concentration and the latter prevents its effect on channel activity.
